---
title: Cavernous Tissue Preservation During Penile Prosthesis Implantation
nct_id: NCT03733860
overall_status: UNKNOWN
phase: NA
sponsor: Cairo University
study_type: INTERVENTIONAL
primary_condition: Erectile Dysfunction
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03733860.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03733860"
ct_last_update_post_date: 2018-11-08
last_seen_at: "2026-05-12T06:09:22.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Cavernous Tissue Preservation During Penile Prosthesis Implantation

**Official Title:** Preservation of Penile Tumescence by Cavernous Tissue Preservation During Penile Prosthesis Implantation

**NCT ID:** [NCT03733860](https://clinicaltrials.gov/study/NCT03733860)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Cairo University
- **Conditions:** Erectile Dysfunction
- **Start Date:** 2018-11-01
- **Completion Date:** 2018-12
- **CT.gov Last Update:** 2018-11-08

## Brief Summary

Spontaneous penile tumescence after penile prosthesis implantation has been previously reported as sporadically occurring during implant surgery. This study aims at systematically preserving residual erectile function, by the preservation of the patients' spontaneous penile tumescence by systematically sparing cavernous tissue during penile prosthesis implantation.

## Detailed Description

Patients undergoing the cavernous tissue sparing penile implant procedure will be injected intraoperatively with 40µg alprostadil, a prostaglandin E1 agonist intracorporal injection (ICI). The procedure will begin as soon as maximal tumescence is attained.

In the cavernous sparing group, corporal dilation will be done solely with a size 8 dilator. The insertion of the dilator will be carefully inserted in what we call the path of least resistance. To determine the path of least resistance, the corporotomy is spread apart by pulling on previously set stay sutures. The path of least resistance is the plane with maximum outflow of blood from the intraoperatively pharmaceutically dilated and blood filled corpora cavernosa. This plane can also be anticipated with a preoperative penile duplex.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 81 Years
- **Sex:** MALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Erectile dysfunction not amenable to treatment by approved medical therapy

Exclusion Criteria:

* Erectile dysfunction amenable to treatment by approved medical therapy
```

## Arms

- **Cavernous sparing group** (ACTIVE_COMPARATOR)
- **Conventional technique group** (OTHER)

## Interventions

- **Cavernous tissue sparing penile prosthesis implantation** (PROCEDURE) — Beginning penile prosthesis implantation (Coloplast Titan USA) procedure after intracavenosal injection of PGE1 prostine.
- **Conventional penile prosthesis implantation** (PROCEDURE) — Beginning penile implant procedure (Coloplast Titan USA) without prior intracavernosal injection of PGE1 prostine
- **Intracavernosal injection of alprostadil** (PROCEDURE) — Intraoperative intracavernosal injection of alprostadil in the cavernous sparing group

## Primary Outcomes

- **Cavernous tissue thickness postoperatively measured by ultrasound** _(time frame: 1 month)_

## Secondary Outcomes

- **Presence of spontaneous penile tumescence post operatively** _(time frame: 1 month)_

## Locations (1)

- Cairo University, Cairo, Egypt

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.cairo university|cairo||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03733860.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03733860*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*